Drugs Research

Novartis’s Ianalumab has positive Phase III results for Sjögren’s Syndrome

HQ Team August. 11, 2025: Novartis AG announced positive Phase III trial results for its experimental autoimmune drug, Ianalumab (VAY736), in treating Sjögren’s.

Read More